Guowen Yin - Department of Interventional Radiology, Cancer Hospital of Jiangsu Province

基本信息

Career Trajectory

Bio

精通全身各部位实体肿瘤及肿瘤相关并发症介入治疗，如肝癌，胰腺癌，胆囊癌，肺癌，头颈部肿瘤及盆腔肿瘤的灌注栓塞，消融及放射性粒子植入治疗。胆管及门脉内支架和放射性粒子条植入，气管及食管，肠道支架植入治疗。肿瘤原因引起的动静脉血管堵塞的血栓溶栓和支架植入，以及DSA下经皮胃造廔建立营养通道，静脉输液港植入术，骨转移瘤成型术。

Research Interests

Papers共 94 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Hepatic Arterial Infusion Chemotherapy (HAIC) Plus Lenvatinib and PD-1 Inhibitors Versus Systemic Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Qingyu Xu, Chendong Wang,Ran You,Bin Leng, Zeyu Yu, Ya Lu, Lingfeng Diao,Hao Jiang, Bei Wu,Guowen Yin

Discover Oncologyno. 1 (2025): 1-14

Cited0Views0WOSBibtex

Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy after Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study

Zeyu Yu,Bin Leng,Ran You, Lingfeng Diao,Qingyu Xu,Guowen Yin

Drugs - Real World Outcomespp.1-9, (2025)

Cited0Views0WOSBibtex

Lenvatinib Plus Immunotherapy Versus Lenvatinib Monotherapy in Lenvatinib-Insensitive Patients with Unresectable Hepatocellular Carcinoma: a Retrospective Study

Zeyu Yu,Bin Leng,Ran You, Chendong Wang, Lingfeng Diao,Qingyu Xu,Guowen Yin

Investigational New Drugspp.1-8, (2025)

Cited0Views0WOSBibtex

Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma (APOLLO): a Randomised, Controlled, Phase 3 Trial

Jian Zhou,Li Bai,Jia Luo,Yuxian Bai,Yaozhen Pan,Xinrong Yang, Yufeng Gao,Rongshu Shi, Wenhua Zhang,Jinfang Zheng, Xiangdong Hua, Aibing Xu,Sheng Hu, Feng Zhang, Xiaojun Yang,Mingxu Da, Rui Wang,Jie Ma,Weidong Jia,Dongmei Quan,Chuang Peng, Wei Yang,Guowen Yin, Yue Qi, Guifang Zhang,Xilin Du,Xiaorong Mao,Zhiqiang Meng,Shunchang Jiao,Jia Fan, APOLLO Study Group

The Lancet Oncologyno. 6 (2025): 719-731

Cited0Views0WOSBibtex

Comparison of Liver Injury and Inflammatory Response Following Conventional and Drug-Eluting Bead Transcatheter Chemoembolization in Hepatocellular Carcinoma

Ran You,Bin Leng, Chendong Wang, Zeyu Yu, Lingfeng Diao, Ya Lu,Qingyu Xu,Guowen Yin

Discover Oncology（2025）

Cited0Views0WOSBibtex

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma

Chendong Wang,Bin Leng,Ran You, Zeyu Yu, Ya Lu, Lingfeng Diao,Hao Jiang, Yuan Cheng,Guowen Yin,Qingyu Xu

JOURNAL OF HEPATOCELLULAR CARCINOMA (2024): 2321-2337

Cited0Views0WOSBibtex

The Efficacy and Safety of Donafenib-Containing Regimens As First-Line Therapy for Hepatocellular Carcinoma (HCC): A Multicenter Retrospective Study

Qingqiao Zhang,Guowen Yin,Qingyu Xu,Jinchang Xiao,Bin Shen, Guofeng Chen, Genshan Zhang, Wei Feng, Yong Yang, Jianping Hu, Chenghu Wang

Journal of Clinical Oncology（2024）

Cited0Views0Bibtex

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and PD-1 Inhibitors Versus Lenvatinib and PD-1 Inhibitors for HCC Refractory to TACE

Lingfeng Diao,Chendong Wang,Ran You,Bin Leng, Zeyu Yu,Qingyu Xu,Yuan Cheng,Guowen Yin

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY（2024）

Cited3Views0WOSBibtex

Immune Checkpoint Inhibitors and Anti-Vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without Transarterial Chemoembolization As First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2201): a Target Trial Emulation Study

EClinicalMedicine (2024): 102622-102622

Cited20Views0WOSBibtex

Comparison of the Efficacy and Safety of Immunotherapy Combined with Lenvatinib at Different Time Points in Unresectable Hepatocellular Carcinoma: a Single-Center Retrospective Study

Zeyu Yu,Bin Leng,Ran You,Chendong Wang, Lingfeng Diao,Qingyu Xu,Guowen Yin

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Guowen Yin(尹国文)

主任医师

Papers共 94 篇Author StatisticsCo-AuthorSimilar Experts